‘Swift’ Vascepa Victory Puts Hikma And Reddy’s In Pole Position
But Analyst Calls Generic Threat ‘Overstated’
Hikma and Dr Reddy’s Laboratories are weighing launches of their generics to Amarin’s Vascepa after the US Court of Appeals for the Federal Circuit upheld a favorable lower court ruling. The originator said it would take its appeal to the next level and continued to raise doubts over supply capacity.
